NSE BSE
divi's laboratories stock

Divi's Laboratories Share Price

- - (%)
Sector: -

10940

532488

DIVISLAB

img img img img
No Data Available

Divi's Laboratories Share Price Update


As of the latest trading session, Divi's Laboratories share price is currently at 4588.6, which is down by -4.89 from its previous closing. Today, the stock has fluctuated between 4559.10 and 4627.95. Over the past year, Divi's Laboratories has achieved a return of 31.70 %. In the last month alone, the return has been 17.43 %.

Divi's Laboratories Performance

Day Range

Low4559.10 High4627.95
4588.60

52 Week Range

Low 3295.30 High 4627.95
4588.60

Open Price

4595.00

Prev. Close

4593.50

Volume (Shares)

281968.00

Total traded value

12938.38

Upper Circuit

5052.85

Lower Circuit

4134.15

Note: The current prices & values are delayed, Login to your account for live updates.

Divi's Laboratories Fundamentals


(Standalone)

Market Cap (Cr) 121812.90
PE Ratio (TTM) 77.36
Book Value / Share 507.93
Beta 0.49
ROE 14.82%
EPS (TTM) 59.37
Dividend Yield 0.65%
Net Profit Qtr (Cr) 531.00

Divi's Laboratories Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars MAR 2024 (Values in Cr)
Revenue 2259.00
Operating Expense 1638.00
Net Profit 531.00
Net Profit Margin (%) 23.50
Earnings Per Share (EPS) 19.99
EBITDA 796.00
Effective Tax Rate (%) 24.14
Particulars DEC 2023 (Values in Cr)
Revenue 1808.00
Operating Expense 1412.00
Net Profit 358.00
Net Profit Margin (%) 19.80
Earnings Per Share (EPS) 13.50
EBITDA 585.00
Effective Tax Rate (%) 26.93
Particulars SEP 2023 (Values in Cr)
Revenue 1868.00
Operating Expense 1489.00
Net Profit 342.00
Net Profit Margin (%) 18.30
Earnings Per Share (EPS) 12.89
EBITDA 559.00
Effective Tax Rate (%) 26.29
Particulars JUN 2023 (Values in Cr)
Revenue 1730.00
Operating Expense 1332.00
Net Profit 345.00
Net Profit Margin (%) 19.94
Earnings Per Share (EPS) 12.99
EBITDA 571.00
Effective Tax Rate (%) 27.82
Particulars MAR 2023 (Values in Cr)
Revenue 1908.00
Operating Expense 1506.00
Net Profit 319.00
Net Profit Margin (%) 16.71
Earnings Per Share (EPS) 12.01
EBITDA 555.00
Effective Tax Rate (%) 31.83
Particulars MAR 2024 (Values in Cr)
Revenue 7665.00
Operating Expense 5870.00
Net Profit 1576.00
Net Profit Margin (%) 20.56
Earnings Per Share (EPS) 59.37
EBITDA 2511.00
Effective Tax Rate (%) 26.07
Particulars MAR 2023 (Values in Cr)
Revenue 7625.00
Operating Expense 5620.00
Net Profit 1808.00
Net Profit Margin (%) 23.71
Earnings Per Share (EPS) 68.11
EBITDA 2697.00
Effective Tax Rate (%) 23.19
Particulars MAR 2022 (Values in Cr)
Revenue 8879.82
Operating Expense 5314.55
Net Profit 2948.54
Net Profit Margin (%) 33.20
Earnings Per Share (EPS) 111.07
EBITDA 3987.72
Effective Tax Rate (%) 19.80
Particulars MAR 2021 (Values in Cr)
Revenue 6798.61
Operating Expense 4233.26
Net Profit 1954.72
Net Profit Margin (%) 28.75
Earnings Per Share (EPS) 73.63
EBITDA 2883.21
Effective Tax Rate (%) 25.61
Particulars MAR 2020 (Values in Cr)
Revenue 5310.57
Operating Expense 3687.14
Net Profit 1372.71
Net Profit Margin (%) 25.84
Earnings Per Share (EPS) 51.71
EBITDA 2005.30
Effective Tax Rate (%) 24.29
Particulars MAR 2023 (Values in Cr)
Book Value / Share 480.96
ROE % 14.89
ROCE % 19.30
Total Debt to Total Equity 0.00
EBITDA Margin 34.94
Particulars MAR 2022 (Values in Cr)
Book Value / Share 441.82
ROE % 28.16
ROCE % 34.96
Total Debt to Total Equity 0.00
EBITDA Margin 44.61
Particulars MAR 2021 (Values in Cr)
Book Value / Share 350.15
ROE % 23.90
ROCE % 31.97
Total Debt to Total Equity 0.00
EBITDA Margin 41.95
Particulars MAR 2020 (Values in Cr)
Book Value / Share 275.38
ROE % 19.30
ROCE % 25.29
Total Debt to Total Equity 0.01
EBITDA Margin 37.31
Particulars MAR 2019 (Values in Cr)
Book Value / Share 262.09
ROE % 21.00
ROCE % 28.44
Total Debt to Total Equity 0.01
EBITDA Margin 41.01
Particulars MAR 2023 (Values in Cr)
Book Value / Share 478.64
ROE % 14.82
ROCE % 19.27
Total Debt to Total Equity 0.00
EBITDA Margin 35.38
Particulars MAR 2022 (Values in Cr)
Book Value / Share 440.44
ROE % 28.13
ROCE % 35.01
Total Debt to Total Equity 0.00
EBITDA Margin 44.92
Particulars MAR 2021 (Values in Cr)
Book Value / Share 349.28
ROE % 23.57
ROCE % 31.55
Total Debt to Total Equity 0.00
EBITDA Margin 42.43
Particulars MAR 2020 (Values in Cr)
Book Value / Share 275.63
ROE % 19.21
ROCE % 25.17
Total Debt to Total Equity 0.01
EBITDA Margin 37.78
Particulars MAR 2019 (Values in Cr)
Book Value / Share 262.70
ROE % 20.61
ROCE % 27.99
Total Debt to Total Equity 0.01
EBITDA Margin 41.12
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 4213.09
Total Assets 14438.77
Total Liabilities 14438.77
Total Equity 12767.09
Share Outstanding 265468580
Price to Book Ratio 5.90
Return on Assets (%) 12.62
Return on Capital (%) 14.28
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2818.88
Total Assets 13374.71
Total Liabilities 13374.71
Total Equity 11728.18
Share Outstanding 265468580
Price to Book Ratio 10.00
Return on Assets (%) 22.13
Return on Capital (%) 25.24
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2156.03
Total Assets 10774.07
Total Liabilities 10774.07
Total Equity 9294.61
Share Outstanding 265468580
Price to Book Ratio 10.39
Return on Assets (%) 18.41
Return on Capital (%) 21.35
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 122.63
Total Assets 8535.70
Total Liabilities 8535.70
Total Equity 7309.92
Share Outstanding 265468580
Price to Book Ratio 7.21
Return on Assets (%) 16.12
Return on Capital (%) 18.74
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 115.26
Total Assets 8038.25
Total Liabilities 8038.25
Total Equity 6957.15
Share Outstanding 265468580
Price to Book Ratio 6.48
Return on Assets (%) 16.82
Return on Capital (%) 19.15
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 4187.56
Total Assets 14351.62
Total Liabilities 14351.62
Total Equity 12705.42
Share Outstanding 265468580
Price to Book Ratio 5.90
Return on Assets (%) 12.59
Return on Capital (%) 14.23
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2803.68
Total Assets 13307.86
Total Liabilities 13307.86
Total Equity 11691.35
Share Outstanding 265468580
Price to Book Ratio 10.00
Return on Assets (%) 22.15
Return on Capital (%) 25.22
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2142.01
Total Assets 10723.77
Total Liabilities 10723.77
Total Equity 9271.57
Share Outstanding 265468580
Price to Book Ratio 10.39
Return on Assets (%) 18.22
Return on Capital (%) 21.08
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 107.36
Total Assets 8514.11
Total Liabilities 8514.11
Total Equity 7316.69
Share Outstanding 265468580
Price to Book Ratio 7.21
Return on Assets (%) 16.12
Return on Capital (%) 18.68
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 105.20
Total Assets 8040.18
Total Liabilities 8040.18
Total Equity 6973.31
Share Outstanding 265468580
Price to Book Ratio 6.48
Return on Assets (%) 16.57
Return on Capital (%) 18.83
Particulars MAR 2023 (Values in Cr)
Net Income 2368.63
Cash from Operations 2932.38
Cash from Investing -2707.62
Cash from Financing -797.17
Net change in Cash -1045.06
Free Cash Flow 3405.40
Particulars MAR 2022 (Values in Cr)
Net Income 3683.50
Cash from Operations 2552.78
Cash from Investing -2194.92
Cash from Financing -532.44
Net change in Cash -815.56
Free Cash Flow 3265.98
Particulars MAR 2021 (Values in Cr)
Net Income 2666.04
Cash from Operations 2591.25
Cash from Investing 75.13
Cash from Financing -34.89
Net change in Cash 1987.17
Free Cash Flow 3501.44
Particulars MAR 2020 (Values in Cr)
Net Income 1819.46
Cash from Operations 1661.17
Cash from Investing -83.47
Cash from Financing -1091.42
Net change in Cash 41.05
Free Cash Flow 2844.38
Particulars MAR 2019 (Values in Cr)
Net Income 1855.07
Cash from Operations 1438.74
Cash from Investing -685.40
Cash from Financing -245.94
Net change in Cash 22.96
Free Cash Flow 2171.81
Particulars MAR 2023 (Values in Cr)
Net Income 2354.10
Cash from Operations 2919.54
Cash from Investing -2706.75
Cash from Financing -796.59
Net change in Cash -1055.39
Free Cash Flow 3391.69
Particulars MAR 2022 (Values in Cr)
Net Income 3676.52
Cash from Operations 2539.95
Cash from Investing -2195.40
Cash from Financing -531.50
Net change in Cash -816.74
Free Cash Flow 3253.62
Particulars MAR 2021 (Values in Cr)
Net Income 2627.87
Cash from Operations 2580.01
Cash from Investing 75.34
Cash from Financing -33.97
Net change in Cash 1988.42
Free Cash Flow 3489.99
Particulars MAR 2020 (Values in Cr)
Net Income 1813.29
Cash from Operations 1654.44
Cash from Investing -81.38
Cash from Financing -1091.25
Net change in Cash 35.84
Free Cash Flow 2837.30
Particulars MAR 2019 (Values in Cr)
Net Income 1833.23
Cash from Operations 1446.98
Cash from Investing -684.24
Cash from Financing -245.94
Net change in Cash 33.88
Free Cash Flow 2179.92
Company Name Price P/E P/B Market Cap 52 Week Low/High
DIVI S LABORATORIES LTD 4593.00 76.21 8.98 121929.72 3300.00 / 4616.00
BLISS GVS PHARMA LTD 105.35 11.51 1.14 1102.92 75.53 / 148.95
CIPLA LTD 1543.45 29.27 4.66 124617.38 973.00 / 1554.40
FERMENTA BIOTECH LIMITED 177.80 0.00 1.80 523.28 132.30 / 214.00
GLAXOSMITHKLINE PHARMA LT 2699.10 69.64 25.72 45724.38 1376.50 / 2708.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
DIVI S LABORATORIES LTD 4593.00 77.36 9.04 121929.72 3300.00 / 4616.00
AMRUTAJAN HEALTH LTD 756.85 48.64 7.58 2188.10 556.05 / 802.60
ASTRAZENECA PHARMA IND LT 6350.95 106.20 22.30 15877.38 3535.00 / 7208.00
BLISS GVS PHARMA LTD 105.35 14.55 1.11 1102.92 75.53 / 148.95
ABBOTT INDIA LIMITED 27612.80 48.85 15.86 58677.20 21907.45 / 29628.15

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 4515.00
  • 26 Days 4281.30
  • 10 Days 4477.40
  • 50 Days 4087.50
  • 12 Days 4467.00
  • 100 Days 3922.80
  • 20 Days 4338.00
  • 200 Days 3713.80
4569.12
PIVOT
First Resistance 4641.38
Second Resistance 4689.27
Third Resistance 4761.53
First Support 4521.23
Second Support 4448.97
Third Support 4401.08
RSI 72.91
MACD 185.70
Commodity Channel Index (CCI) 101.63
ADX 34.37
Williams % R -5.38

Over 1 Month

down

17.43

Over 3 Months

down

32.00

Over 6 Months

down

25.64

Over 1 Year

down

31.70

Over 3 Years

down

1.53

Over 5 Years

down

24.32

Divi's Laboratories Future

Future: Price

30 May
3901.10
27 Jun
3932.00
25 Jul
3956.95
25 May
0 100 200 300 400 500 600

Discount/Premium

27 Jun
3.90
25 Jul
29.35
29 Aug
31.40
25 May
0 1 2 3 4 5 6 7

Active Calls

4000.0
903
3900.0
640
4200.0
364
25 May
0 500 1000 1500 2000 2500 3000

Active Puts

3900.0
339
3800.0
299
3700.0
173
25 Jul
0 500 1000 1500 2000 2500

Divi's Laboratories Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Others
19.11
Promoter Holdings
51.92
FII
14.68
DII
14.28
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Nilima Prasad Divi Shareholding of Promoter and Promoter Group 5.4E7 20.34
Satchandra Kiran Divi Shareholding of Promoter and Promoter Group 5.4E7 20.34
Sbi Mutual Fund Public Shareholding 2.0844087E7 7.85
Life Insurance Corporation Of India Public Shareholding 1.616811E7 6.09
Swarna Latha Divi Shareholding of Promoter and Promoter Group 1.4E7 5.27
Divi's Biotech Private Limited Shareholding of Promoter and Promoter Group 8000000.0 3.01
Murali Krishna Prasad Divi Shareholding of Promoter and Promoter Group 7567000.0 2.85
Axis Mutual Fund Trustee Limited Public Shareholding 4476276.0 1.69
Government Pension Fund Global Public Shareholding 3274174.0 1.23
Madhusudana Rao Divi Shareholding of Promoter and Promoter Group 266690.0 0.1
Radhakrishna Rao Divi Shareholding of Promoter and Promoter Group 0.0 0.0

Divi's Laboratories

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2023-08-11 30.0 Final 2023-08-11 Equity shares 2022-08-11 30.0 Final 2022-08-12 Equity shares 2021-08-17 20.0 Final 2021-08-20 Equity shares 2020-02-25 16.0 Interim 2020-02-26 Equity shares 2019-08-14 16.0 Final 2019-08-17 Equity shares 2018-08-31 10.0 Final 2018-09-04 Equity shares 2017-09-15 10.0 Final 2017-09-19 Equity shares 2016-03-17 10.0 Interim 2016-03-18 Equity shares 2015-08-06 20.0 Final 2015-08-10 Equity shares 2014-07-31 20.0 Final 2014-08-04 Equity shares 2013-07-25 15.0 Final 2013-07-29 Equity shares 2012-07-26 13.0 Final 2012-07-30 Equity shares 2011-06-16 10.0 Final 2011-06-18 Equity shares 2010-07-02 6.0 Final 2010-07-06 Equity shares 2009-06-15 6.0 Final 2009-06-17 Equity shares 2008-06-26 4.0 Final 2008-06-28 Equity shares 2007-03-23 2.0 Interim 2007-03-26 Equity shares 2005-08-11 0.0 Final 2005-08-13 Equity shares
Ex-Date Ex-Bonus Ratio
2015-09-26 2015-09-23 1:1 2009-08-01 2009-07-30 1:1
Ex-Date Old FV NEW FV Record Date
2007-08-03 10.0 2.0 2007-08-10

Learn More About Stocks

Divi's Laboratories Limited Overview

Since its inception in 1990, Divis Laboratories Ltd has carved a niche in manufacturing and exporting APIs, intermediates, and Nutraceutical ingredients, catering to the global pharmaceutical and nutraceutical industries. With a portfolio that includes 30 high-volume generic APIs, custom synthesis services for top pharma companies, and a specialised unit for carotenoids in Visakhapatnam, Divis stands out for its extensive range and global reach. The company boasts six multi-purpose manufacturing facilities in Telangana and Visakhapatnam, recognized among the largest API production sites worldwide, with a significant reactor capacity and multiple cGMP and customer quality audits. Offering a diverse product list across various therapeutic categories, Divis Laboratories is a global leader in Naproxen and has a strong international presence with marketing subsidiaries in the USA and Switzerland. The majority of its revenue comes from product sales, heavily weighted towards exports, especially to Europe and North America. Moving forward, Divis is expanding with a new manufacturing site in Kakinada and investing in cutting-edge technologies, underscoring its commitment to innovation and growth in the pharmaceutical sector.

About Divi's Laboratories

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by Divi's Laboratories

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 5x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Divis Laboratories Ltd?

Answer Field

The share price of Divis Laboratories Ltd for NSE is ₹ 4588.6 and for BSE is ₹ 4586.75.

What is the Market Cap of Divis Laboratories Ltd?

Answer Field

The market cap of Divis Laboratories Ltd for NSE is ₹ 1,21,812.90 Cr. and for BSE is ₹ 1,21,763.80 Cr. as of now.

What is the 52 Week High and Low of Divis Laboratories Ltd?

Answer Field

The 52 Week High and Low of Divis Laboratories Ltd for NSE is ₹ 4627.95 and ₹ 3295.30 and for BSE is ₹ 4625.00 and ₹ 3300.00.

How to Buy Divis Laboratories Ltd share?

Answer Field

You can trade in Divis Laboratories Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Divis Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been 31.70%.

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

7 Lac+ Users

icon-with-text

4.5+ App Rating

icon-with-text

4 Languages

icon-with-text

₹ 3800 Cr MTF Book

icon-with-text
loader